Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ischemic Heart Disease

  Free Subscription


Articles published in J Cardiovasc Pharmacol

Retrieve available abstracts of 139 articles:
HTML format



Single Articles


    July 2021
  1. LI Y, Meng W, Hou Y, Li D, et al
    Dual Role of Mitophagy in Cardiovascular Diseases.
    J Cardiovasc Pharmacol. 2021;78:e30-e39.
    PubMed     Abstract available


    June 2021
  2. HAMMOUD S, Kurdi M, van den Bemt BJ
    Impact of Fasting on Cardiovascular Outcomes in Patients with Hypertension.
    J Cardiovasc Pharmacol. 2021 Jun 29. pii: 00005344-900000000-98181.
    PubMed     Abstract available


  3. HAO L, Wang J, Bi SJ, Cheng C, et al
    Upregulation of lncRNA FGD5-AS1 ameliorates myocardial ischemia/reperfusion injury via miR-106a-5p and miR-106b-5p.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98185.
    PubMed     Abstract available


  4. LOU YM, Zheng ZL, Xie LY, Lian JF, et al
    Effects of spironolactone on hypoxia-inducible factor-1alpha in the patients receiving coronary artery bypass grafting.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98182.
    PubMed     Abstract available


  5. ZHANG J, Tang Y, Zhang J, Wang J, et al
    CircRNA ACAP2 is overexpressed in myocardial infarction and promotes the maturation of miR-532 to induce the apoptosis of cardiomyocyte.
    J Cardiovasc Pharmacol. 2021 Jun 15. pii: 00005344-900000000-98198.
    PubMed     Abstract available


  6. LI Y, Ren X, Fang Z
    Systematic Review and Meta-analysis: The Effects of Prophylactic Proton Pump Inhibitor Treatment in Patients With Coronary Heart Disease Receiving Dual Antiplatelet Therapy.
    J Cardiovasc Pharmacol. 2021;77:835-861.
    PubMed     Abstract available


  7. WATSON K, Kukin A, Wasik AK, Shulenberger CE, et al
    Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease.
    J Cardiovasc Pharmacol. 2021;77:685-698.
    PubMed     Abstract available


    May 2021
  8. LIU X, Hua Y, Hu M, Wu K, et al
    Knockdown of lncRNA Abhd11os attenuates myocardial ischemia/reperfusion injury by inhibiting apoptosis in cardiomyocytes.
    J Cardiovasc Pharmacol. 2021 May 31. pii: 00005344-900000000-98212.
    PubMed     Abstract available


  9. IQBAL J, Chamberlain J, Alfaidi M, Hughes M, et al
    Carbon monoxide releasing molecule A1 reduces myocardial damage after acute myocardial infarction in a porcine model.
    J Cardiovasc Pharmacol. 2021 May 20. pii: 00005344-900000000-98224.
    PubMed     Abstract available


  10. YUAN JL, Yin CY, Li YZ, Song S, et al
    EZH2 as an epigenetic regulator of cardiovascular development and diseases.
    J Cardiovasc Pharmacol. 2021 May 19. pii: 00005344-900000000-98225.
    PubMed     Abstract available


  11. CATURANO A
    Bivalirudin use for Primary Percutaneous Coronary Intervention on Long term Mortality.
    J Cardiovasc Pharmacol. 2021 May 5. pii: 00005344-900000000-98249.
    PubMed    


  12. YANG T, Gu J, Du C, Shan T, et al
    Adverse Cerebral Cardiovascular Events Associated With Checkpoint Kinase 1 Inhibitors: A Systemic Review.
    J Cardiovasc Pharmacol. 2021;77:549-556.
    PubMed     Abstract available


    April 2021
  13. JAGADISH PS, Le FK, Labroo A, Nasr A, et al
    A Meta-analysis of Clinical Trials Evaluating the Impact of Bivalirudin-based Anticoagulation for Primary Percutaneous Coronary on Long term Mortality.
    J Cardiovasc Pharmacol. 2021 Apr 22. pii: 00005344-900000000-98253.
    PubMed     Abstract available


  14. PENG Q, Li L, Bi X
    Long non-coding RNA SNHG7 knockdown protects mouse cardiac fibroblasts against myocardial infarction by regulating miR-455-3p/PTAFR axis.
    J Cardiovasc Pharmacol. 2021 Apr 21. pii: 00005344-900000000-98257.
    PubMed     Abstract available


  15. SALLAM MY, El-Gowilly SM, El-Mas MM
    Cardiac and brainstem neuroinflammatory pathways account for androgenic incitement of cardiovascular and autonomic manifestations in endotoxic male rats.
    J Cardiovasc Pharmacol. 2021 Apr 9. pii: 00005344-900000000-98265.
    PubMed     Abstract available


  16. LU Y, Yuan W, Wang L, Ning M, et al
    Contribution of lncRNA CASC8, CASC11 and PVT1 genetic variants to the susceptibility of coronary heart disease.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98242.
    PubMed     Abstract available


  17. JIAO F, Varghese K, Wang S, Liu Y, et al
    Recent Insights into the Protective Mechanisms of Paeoniflorin in Neurological, Cardiovascular, and Renal Diseases.
    J Cardiovasc Pharmacol. 2021 Apr 5. pii: 00005344-900000000-98240.
    PubMed     Abstract available



  18. Essential Role of the ELABELA-APJ Signaling Pathway in Cardiovascular System Development and Diseases: Erratum.
    J Cardiovasc Pharmacol. 2021;77:529.
    PubMed    


  19. TANNER R, Cronin M, Macken L, Murphy R, et al
    Real-World Experience With Antiplatelet Agents After Percutaneous Coronary Intervention in Patients With an Indication for an Oral Anticoagulant.
    J Cardiovasc Pharmacol. 2021;77:501-507.
    PubMed     Abstract available


    February 2021
  20. VILHENA JC, Lopes de Melo Cunha L, Jorge TM, de Lucena Machado M, et al
    Acai reverses adverse cardiovascular remodeling in renovascular hypertension: a comparative effect with Enalapril.
    J Cardiovasc Pharmacol. 2021 Feb 19. pii: 00005344-900000000-98275.
    PubMed     Abstract available


  21. ZEYI Z, Ou C
    Efficacy and Safety of Ticagrelor in Diabetes Patients Undergoing Percutaneous Coronary Intervention: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2021 Feb 18. pii: 00005344-900000000-98271.
    PubMed     Abstract available


  22. HAN Y, Hua S, Chen Y, Yang W, et al
    Circulating PGLYRP1 levels as a potential biomarker for coronary artery disease and heart failure.
    J Cardiovasc Pharmacol. 2021 Feb 18. pii: 00005344-900000000-98269.
    PubMed     Abstract available


  23. ZHANG C, Jin DD, Wang XY, Lou L, et al
    Key Enzymes for the Mevalonate Pathway in the Cardiovascular System.
    J Cardiovasc Pharmacol. 2021;77:142-152.
    PubMed     Abstract available


    January 2021
  24. GRAGNANO F, Calabro P, Cattano D
    Antithrombotic Therapy in Patients Taking Oral Anticoagulants and Undergoing Percutaneous Coronary Intervention: Time to Be Bold and Wise.
    J Cardiovasc Pharmacol. 2021 Jan 13. pii: 00005344-900000000-98288.
    PubMed    


  25. LEMOINE MD, Christ T
    Human induced pluripotent stem cell derived cardiomyocytes: the new working horse in cardiovascular pharmacology?
    J Cardiovasc Pharmacol. 2021;Publish Ahead of Print.
    PubMed    


  26. KAKAVAND H, Aghakouchakzadeh M, Coons J, Talasaz AH, et al
    Pharmacologic Prevention of Myocardial Ischemia-Reperfusion Injury in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    J Cardiovasc Pharmacol. 2021;Publish Ahead of Print.
    PubMed     Abstract available


    December 2020
  27. CORDERO A, Ferreiro JL, Bertomeu-Gonzalez V, Rodriguez-Manero M, et al
    Direct oral anticoagulants vs. vitamin K antagonist after percutaneous coronary interventions in patients with atrial fibrillation: a metanalysis of cardiac ischemic events.
    J Cardiovasc Pharmacol. 2020;Publish Ahead of Print.
    PubMed     Abstract available


  28. ABDU FA, Liu L, Mohammed AQ, Xu B, et al
    Effect of Secondary Prevention Medication on the Prognosis in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease.
    J Cardiovasc Pharmacol. 2020;76:678-683.
    PubMed     Abstract available


    November 2020
  29. WANG R, Peng L, Lv D, Shang F, et al
    Leonurine Attenuates Myocardial Fibrosis through Upregulation of miR-29a-3p in Mice Post-myocardial Infarction.
    J Cardiovasc Pharmacol. 2020 Nov 17. doi: 10.1097/FJC.0000000000000957.
    PubMed     Abstract available


  30. NORDBECK P, Hu K
    The trend is your friend: DOACs as standard anticoagulants for patients with atrial fibrillation undergoing percutaneous coronary interventions.
    J Cardiovasc Pharmacol. 2020 Nov 3. doi: 10.1097/FJC.0000000000000950.
    PubMed    


  31. HUANG B, Xu C, Liu H, Deng W, et al
    In-Hospital Management and Outcomes of Acute Myocardial Infarction Before and During the Coronavirus Disease 2019 Pandemic.
    J Cardiovasc Pharmacol. 2020;76:540-548.
    PubMed     Abstract available


  32. MA H, Zheng L, Qin H, Wang W, et al
    Myocardial Infarction-associated Transcript Knockdown Inhibits Cell Proliferation, Migration, and Invasion Through miR-490-3p/Intercellular Adhesion Molecule 1 Axis in Oxidized Low-density Lipoprotein-induced Vascular Smooth Muscle Cells.
    J Cardiovasc Pharmacol. 2020;76:617-626.
    PubMed     Abstract available


  33. BHATTARAI M, Ibrahim AM, Salih M, Tandan N, et al
    Comprehensive Outcomes Evaluation After Percutaneous Coronary Intervention in Stable Ischemic Heart Disease and Acute Coronary Syndrome for Short- Versus Standard-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-analysis of Randomized Cont
    J Cardiovasc Pharmacol. 2020;76:574-583.
    PubMed     Abstract available


    October 2020
  34. ZHANG P, Yu Y, Wang P, Shen H, et al
    Role of Hydrogen Sulfide in Myocardial Ischemia-Reperfusion Injury.
    J Cardiovasc Pharmacol. 2020 Oct 30. doi: 10.1097/FJC.0000000000000943.
    PubMed     Abstract available


  35. SANGWOO P, Yong-Giun K, Soe Hee A, Hyun Woo P, et al
    Angiotensin Converting Enzyme Inhibitor versus Angiotensin Receptor Blocker Based Optimal Medical Therapy after Percutaneous Coronary Intervention: A Nationwide Cohort Study.
    J Cardiovasc Pharmacol. 2020 Oct 30. doi: 10.1097/FJC.0000000000000930.
    PubMed     Abstract available


  36. CALCAGNO S, Di Pietro R, Biondi-Zoccai G, Versaci F, et al
    Renin-angiotensin blocking therapies: a must - but how? - after percutaneous coronary intervention.
    J Cardiovasc Pharmacol. 2020 Oct 23. doi: 10.1097/FJC.0000000000000941.
    PubMed    


  37. MUHAMMAD HAISUM M, Mahboob A, Dan A, Yochai B, et al
    Efficacy of Long-term Oral Beta-blocker Therapy in Patients Who Underwent Percutaneous Coronary Intervention for ST-segment Elevation Myocardial Infarction with Preserved Left Ventricular Ejection Fraction: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2020 Oct 22. doi: 10.1097/FJC.0000000000000922.
    PubMed     Abstract available


  38. QIU M, Ding LL, Wei XB, Liu SY, et al
    Comparative efficacy of GLP-1 RAs and SGLT2is for prevention of major adverse cardiovascular events in type 2 diabetes: a network meta-analysis.
    J Cardiovasc Pharmacol. 2020 Oct 22. doi: 10.1097/FJC.0000000000000916.
    PubMed     Abstract available


  39. NAJAFIPOUR H, Rostamzadeh F, Yeganeh-Hajahmadi M, Joukar S, et al
    Improvement of cardiac function in rats with myocardial infarction by low- to moderate-intensity endurance exercise is associated with normalization of Klotho and SIRT1.
    J Cardiovasc Pharmacol. 2020 Oct 15. doi: 10.1097/FJC.0000000000000935.
    PubMed     Abstract available


  40. ZHANG Y, Wen W, Liu H
    The Role of Immune Cells in Cardiac Remodeling After Myocardial Infarction.
    J Cardiovasc Pharmacol. 2020;76:407-413.
    PubMed     Abstract available


  41. ORTIZ VD, Turck P, Teixeira R, Bello-Klein A, et al
    Effects of carvedilol and thyroid hormones co-administration on apoptotic and survival proteins in the heart following acute myocardial infarction.
    J Cardiovasc Pharmacol. 2020 Oct 1. doi: 10.1097/FJC.0000000000000923.
    PubMed     Abstract available


  42. KRAUS L, Mohsin S
    Role of Stem Cell Derived Microvesicles in Cardiovascular Disease.
    J Cardiovasc Pharmacol. 2020 Oct 1. doi: 10.1097/FJC.0000000000000920.
    PubMed     Abstract available


    September 2020
  43. WANG Q, Liang C
    The Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients with Acute Coronary Syndrome.
    J Cardiovasc Pharmacol. 2020 Sep 24. doi: 10.1097/FJC.0000000000000914.
    PubMed     Abstract available


  44. LIAO S, Zhou Q, Zhang Y
    ABCA1 Polymorphism Is Associated With the Warfarin-Induced Aortic Stiffness After Coronary Artery Bypass Surgery in the Chinese Population.
    J Cardiovasc Pharmacol. 2020;76:360-366.
    PubMed     Abstract available


    August 2020
  45. LI C, Xia W, Wang L, Zhang J, et al
    Effect of renal denervation on cardiac function and inflammatory factors in heart failure after myocardial infarction.
    J Cardiovasc Pharmacol. 2020 Aug 24. doi: 10.1097/FJC.0000000000000899.
    PubMed     Abstract available


  46. ZHAO H, Zhang D
    Percutaneous coronary intervention compared to coronary artery bypass graft surgery for patients with three-vessel disease.
    J Cardiovasc Pharmacol. 2020 Aug 19. doi: 10.1097/FJC.0000000000000888.
    PubMed     Abstract available


  47. BIONDI-ZOCCAI G, Frati G, Miraldi F, Chiariello GA, et al
    A clinical conundrum: three management strategies for three-vessel coronary artery disease?
    J Cardiovasc Pharmacol. 2020 Aug 7. doi: 10.1097/FJC.0000000000000900.
    PubMed    


  48. NORDBECK P, Hu K
    Choosing Wisely: Cardiovascular Drug Therapy in the Era of COVID-19.
    J Cardiovasc Pharmacol. 2020;76:123-124.
    PubMed    


  49. TCHENG JE, Gibson M, Krucoff MW, Patel MR, et al
    SUPPORT-1 (Subjects Undergoing PCI and Perioperative Reperfusion Treatment): A Prospective, Randomized Trial of CMX-2043 in Patients Undergoing Elective Percutaneous Coronary Intervention.
    J Cardiovasc Pharmacol. 2020;76:189-196.
    PubMed     Abstract available


  50. MCGINLEY C, Mordi IR, Kelly P, Currie P, et al
    Prehospital Administration of Unfractionated Heparin in ST-Segment Elevation Myocardial Infarction Is Associated With Improved Long-Term Survival.
    J Cardiovasc Pharmacol. 2020;76:159-163.
    PubMed     Abstract available


  51. LIN Y, Huang S, Chen Y, Wu Z, et al
    Helix B Surface Peptide Protects Cardiomyocytes From Hypoxia/Reoxygenation-induced Autophagy Through the PI3K/Akt Pathway.
    J Cardiovasc Pharmacol. 2020;76:181-188.
    PubMed     Abstract available


    July 2020
  52. QIAN B, Zhao Q, Ye X
    Ultrasound and magnetic responsive drug delivery systems for cardiovascular application.
    J Cardiovasc Pharmacol. 2020 Jul 16. doi: 10.1097/FJC.0000000000000885.
    PubMed     Abstract available


    June 2020
  53. FARSHIDI H, Sobhani AR, Eslami M, Azarkish F, et al
    Magnesium Sulfate Administration in Moderate Coronary Artery Disease Patients Improves Atherosclerotic Risk Factors: A Double Blind Clinical Trial Study.
    J Cardiovasc Pharmacol. 2020 Jun 25. doi: 10.1097/FJC.0000000000000874.
    PubMed     Abstract available


  54. CESARO A, Taglialatela V, Gragnano F, Moscarella E, et al
    Low-dose Ticagrelor in Patients With High Ischemic Risk and Prior Myocardial Infarction: a Multicenter Prospective Real-World Observational Study.
    J Cardiovasc Pharmacol. 2020 Jun 17. doi: 10.1097/FJC.0000000000000856.
    PubMed     Abstract available


  55. ZHAO G, Hailati J, Ma X, Bao Z, et al
    LncRNA Gm4419 regulates myocardial ischemia/reperfusion injury through targeting the miR-682/TRAF3 axis.
    J Cardiovasc Pharmacol. 2020 Jun 17. doi: 10.1097/FJC.0000000000000867.
    PubMed     Abstract available


  56. HAMID A, Vaduganathan M, Oshunbade A, Ayyalasomayajula KK, et al
    Antihyperglycemic Therapies with Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns within an Academic Medical Center.
    J Cardiovasc Pharmacol. 2020 Jun 17. doi: 10.1097/FJC.0000000000000864.
    PubMed     Abstract available


  57. DANG TA, Schunkert H, Kessler T
    cGMP Signaling in Cardiovascular Diseases: Linking Genotype and Phenotype.
    J Cardiovasc Pharmacol. 2020;75:516-525.
    PubMed     Abstract available


    May 2020
  58. ZHANG C, Yang JB, Quan W, Feng YD, et al
    Activation of Paraventricular Melatonin Receptor 2 Mediates Melatonin- conferred Cardio-protection Against Myocardial Ischemia/Reperfusion Injury.
    J Cardiovasc Pharmacol. 2020 May 13. doi: 10.1097/FJC.0000000000000851.
    PubMed     Abstract available


  59. NAVASIOLAVA N, Degryse B, Custaud MA, Moyna NM, et al
    Deciphering the mechanisms behind Cardiovascular Disease: long non-coding RNAs as key molecular signalling hubs and biomarkers of Atherosclerosis.
    J Cardiovasc Pharmacol. 2020 May 5. doi: 10.1097/FJC.0000000000000863.
    PubMed    


  60. COLAREDA GA, Ragone MI, Bonazzola P, Consolini AE, et al
    The mKATP Channels and protein-kinase C Are Involved in the Cardioprotective Effects of Genistein on Estrogen-Deficient Rat Hearts Exposed to Ischemia/Reperfusion: Energetic Study.
    J Cardiovasc Pharmacol. 2020;75:460-474.
    PubMed     Abstract available


    April 2020
  61. YAN M, Liu Q, Jiang Y, Wang B, et al
    Long non-coding RNA LNC_000898 alleviates cardiomyocyte apoptosis and promotes cardiac repair after myocardial infarction via modulating miR-375/PDK1 axis.
    J Cardiovasc Pharmacol. 2020 Apr 16. doi: 10.1097/FJC.0000000000000845.
    PubMed     Abstract available


  62. KISHORE R, Garikipati VNS, Gonzalez C
    Role of circular RNAs in Cardiovascular Disease.
    J Cardiovasc Pharmacol. 2020 Apr 16. doi: 10.1097/FJC.0000000000000841.
    PubMed     Abstract available


  63. BUCKLEY LF, Cheng JWM, Desai A
    Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.
    J Cardiovasc Pharmacol. 2020 Apr 13. doi: 10.1097/FJC.0000000000000840.
    PubMed     Abstract available


  64. DIXON DL, Van Tassell BW, Vecchie A, Bonaventura A, et al
    Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19).
    J Cardiovasc Pharmacol. 2020 Apr 2. doi: 10.1097/FJC.0000000000000836.
    PubMed     Abstract available


  65. ZHOU TT, Wang XY, Huang J, Deng YZ, et al
    Mitochondrial Translocation of DJ-1 Is Mediated by Grp75: Implication in Cardioprotection of Resveratrol Against Hypoxia/Reoxygenation-Induced Oxidative Stress.
    J Cardiovasc Pharmacol. 2020;75:305-313.
    PubMed     Abstract available


    March 2020
  66. LI S, Sun L, Qi L, Jia Y, et al
    Effect of high homocysteine level on the severity of coronary heart disease and prognosis after stent implantation.
    J Cardiovasc Pharmacol. 2020 Mar 18. doi: 10.1097/FJC.0000000000000829.
    PubMed     Abstract available


  67. ZHONG L, Jia J, Ye G
    Rian/miR-210-3p/Nfkb1 feedback loop promotes hypoxia-induced cell apoptosis in myocardial infarction via deactivating PI3K/Akt signaling pathway.
    J Cardiovasc Pharmacol. 2020 Mar 13. doi: 10.1097/FJC.0000000000000824.
    PubMed     Abstract available


  68. CHEN K, He L, Li Y, Li X, et al
    Inhibition of GPR35 Preserves Mitochondrial Function after Myocardial Infarction by Targeting Calpain 1/2.
    J Cardiovasc Pharmacol. 2020 Mar 5. doi: 10.1097/FJC.0000000000000819.
    PubMed     Abstract available


  69. WEI CY, Wang YM, Han L, Chen FF, et al
    Nitrate esters alleviated coronary atherosclerosis via inhibition of NF-kappaB-regulated macrophage polarization shift in epicardial adipose tissue.
    J Cardiovasc Pharmacol. 2020 Mar 3. doi: 10.1097/FJC.0000000000000818.
    PubMed     Abstract available


    February 2020
  70. WANG S, Li B, Li X, Wu L, et al
    Low-intensity ultrasound modulation may prevent myocardial infarction induced sympathetic neural activation and ventricular arrhythmia.
    J Cardiovasc Pharmacol. 2020 Feb 17. doi: 10.1097/FJC.0000000000000810.
    PubMed     Abstract available


  71. BAIR TL, May HT, Knowlton KU, Anderson JL, et al
    Predictors of Statin Intolerance in Patients with a New Diagnosis of Atherosclerotic Cardiovascular Disease Within a Large Integrated Healthcare Institution: The IMPRES Study.
    J Cardiovasc Pharmacol. 2020 Feb 17. doi: 10.1097/FJC.0000000000000808.
    PubMed     Abstract available


  72. LU WH, Zhang WQ, Zhao YJ, Gao YT, et al
    Case-control Study on the Interaction Effects of rs10757278 Polymorphisms at 9p21 Locus and Traditional Risk Factors on Coronary Heart Disease in Xinjiang, China.
    J Cardiovasc Pharmacol. 2020 Feb 10. doi: 10.1097/FJC.0000000000000807.
    PubMed     Abstract available


  73. SAMARDZIC J, Bozina N, Skoric B, Ganoci L, et al
    Impact of Continuous P2Y12 Inhibition Tailoring in Acute Coronary Syndrome and Genetically Impaired Clopidogrel Absorption.
    J Cardiovasc Pharmacol. 2020;75:174-179.
    PubMed     Abstract available


    January 2020
  74. ZHOU S, Wang J, Wang Q, Meng Z, et al
    Essential role of the ELABELA-APJ signaling pathway in cardiovascular system development and diseases.
    J Cardiovasc Pharmacol. 2020 Jan 29. doi: 10.1097/FJC.0000000000000803.
    PubMed     Abstract available


  75. HAN CL, Qu CZ
    Cardiovascular risk and safety evaluation of a dual peroxisome proliferator-activated receptor-alpha/gamma agonist, aleglitazar, in type 2 diabetes patients: A meta-analysis.
    J Cardiovasc Pharmacol. 2020 Jan 9. doi: 10.1097/FJC.0000000000000796.
    PubMed     Abstract available


  76. GARCIA-ROPERO A, Vargas-Delgado AP, Santos-Gallego CG, Badimon JJ, et al
    Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of Aspirin Era?
    J Cardiovasc Pharmacol. 2020 Jan 8. doi: 10.1097/FJC.0000000000000795.
    PubMed     Abstract available


  77. CHOU CC, Lee HL, Huang YC, Wo HT, et al
    Single Bolus Rosuvastatin Accelerates Calcium Uptake and Attenuates Conduction Inhomogeneity in Failing Rabbit Hearts With Regional Ischemia-Reperfusion Injury.
    J Cardiovasc Pharmacol. 2020;75:64-74.
    PubMed     Abstract available


  78. ZHANG J, Yao M, Jia X, Xie J, et al
    Hexokinase II Upregulation Contributes to Asiaticoside-Induced Protection of H9c2 Cardioblasts During Oxygen-Glucose Deprivation/Reoxygenation.
    J Cardiovasc Pharmacol. 2020;75:84-90.
    PubMed     Abstract available


    December 2019
  79. XIE C, Zhu M, Hu Y, Wang K, et al
    Effect of intensive and standard lipid-lowering therapy on the progression of stroke in patients with coronary artery syndromes: a meta-analysis of randomized controlled trials.
    J Cardiovasc Pharmacol. 2019 Dec 24. doi: 10.1097/FJC.0000000000000784.
    PubMed     Abstract available


  80. LI R, Liu R, Yan F, Zhuang X, et al
    Inhibition of TRPA1 Promotes Cardiac Repair in Mice after Myocardial Infarction.
    J Cardiovasc Pharmacol. 2019 Dec 18. doi: 10.1097/FJC.0000000000000783.
    PubMed     Abstract available


  81. BIRNBAUM Y, Ye Y, Perez-Polo JR
    Does Inhibition of Nuclear Factor kappa B Explain the Protective Effect of Ticagrelor on Myocardial Ischemia Reperfusion Injury?
    J Cardiovasc Pharmacol. 2019 Dec 12. doi: 10.1097/FJC.0000000000000787.
    PubMed    


  82. ZHAO L, Hu M, Yang L, Xu H, et al
    Quantitative Association Between Serum/Dietary Magnesium and Cardiovascular Disease/Coronary Heart Disease Risk: A Dose-Response Meta-analysis of Prospective Cohort Studies.
    J Cardiovasc Pharmacol. 2019;74:516-527.
    PubMed     Abstract available


  83. DAS UN
    Commentary on Zhao et al Manuscript Entitled: "Quantitative Association Between Serum/Dietary Magnesium and Cardiovascular Disease/Coronary Heart Disease Risk: A Dose-Response Meta-analysis of Prospective Cohort Studies": Magnesium and Cardiovascular
    J Cardiovasc Pharmacol. 2019;74:508-510.
    PubMed    


    November 2019
  84. BEJJANI AT, Saab SA, Muhieddine DH, Habeichi NJ, et al
    Spatiotemporal Dynamics of Immune Cells in Early Left Venticular Remodeling after Acute Myocardial Infarction in Mice.
    J Cardiovasc Pharmacol. 2019 Nov 20. doi: 10.1097/FJC.0000000000000777.
    PubMed     Abstract available


  85. AMERI K, Bayardorj D, Samurkashian R, Fredkin M, et al
    Administration of Interleukin-15 peptide improves cardiac function in a mouse model of myocardial infarction.
    J Cardiovasc Pharmacol. 2019 Nov 20. doi: 10.1097/FJC.0000000000000764.
    PubMed     Abstract available


  86. ZHANG J, Pan J, Yang M, Jin X, et al
    Upregulating MicroRNA-203 Alleviates Myocardial Remodeling and Cell Apoptosis Through Downregulating Protein Tyrosine Phosphatase 1B in Rats With Myocardial Infarction.
    J Cardiovasc Pharmacol. 2019;74:474-481.
    PubMed     Abstract available


  87. AL-CHALABI A, Heunks LMA, Papp Z, Pollesello P, et al
    Potential of the Cardiovascular Drug Levosimendan in the Management of Amyotrophic Lateral Sclerosis: An Overview of a Working Hypothesis.
    J Cardiovasc Pharmacol. 2019;74:389-399.
    PubMed     Abstract available



  88. The Novel Inodilator ORM-3819 Relaxes Isolated Porcine Coronary Arteries: Role of Voltage-Gated Potassium Channel Activation: Erratum.
    J Cardiovasc Pharmacol. 2019;74:481.
    PubMed    


    October 2019
  89. LIU Y, Li P, Qiao C, Wu T, et al
    Chitosan Hydrogel Enhances the Therapeutic Efficacy of BMSCs for Myocardial Infarction by Alleviating Vascular Endothelial Cell Pyroptosis.
    J Cardiovasc Pharmacol. 2019 Oct 24. doi: 10.1097/FJC.0000000000000760.
    PubMed     Abstract available


    September 2019
  90. YAMAGATA K, Yamori Y
    Inhibition of Endothelial Dysfunction by Dietary Flavonoids and Preventive Effects Against Cardiovascular Disease.
    J Cardiovasc Pharmacol. 2019 Sep 21. doi: 10.1097/FJC.0000000000000757.
    PubMed     Abstract available


  91. YU Y, Sun J, Liu J, Wang P, et al
    Ginsenoside Re preserves cardiac function and ameliorates left ventricular remodeling in a rat model of myocardial infarction.
    J Cardiovasc Pharmacol. 2019 Sep 14. doi: 10.1097/FJC.0000000000000752.
    PubMed     Abstract available


  92. ABBATE A, Booz GW
    Cardiovascular Pharmacology of the NLRP3 Inflammasome.
    J Cardiovasc Pharmacol. 2019;74:173-174.
    PubMed    


    August 2019
  93. ZHANG J, Pan J, Yang M, Jin X, et al
    Up-regulating microRNA-203 alleviates myocardial remodeling and cell apoptosis through down-regulating PTP1B in rats with myocardial infarction.
    J Cardiovasc Pharmacol. 2019 Aug 10. doi: 10.1097/FJC.0000000000000733.
    PubMed     Abstract available


    July 2019
  94. GHAFFARZADEH A, Bagheri M, Khadem-Vatani K, Rad IA, et al
    Association of MMP-1 (rs1799750)-1607 2G/2G and MMP-3 (rs3025058)-1612 6A/6A genotypes with coronary artery disease risk among Iranian Turks.
    J Cardiovasc Pharmacol. 2019 Jul 25. doi: 10.1097/FJC.0000000000000727.
    PubMed     Abstract available


  95. ABBATE A, Booz GW
    Cardiovascular Pharmacology of the NLRP3 Inflammasome.
    J Cardiovasc Pharmacol. 2019 Jul 24. doi: 10.1097/FJC.0000000000000725.
    PubMed    


  96. LU S, Zhong J, Zhang Y, Huang K, et al
    CYP17A1 Polymorphisms are Linked to the Risk of Coronary Heart Disease in A Case-control Study.
    J Cardiovasc Pharmacol. 2019 Jul 22. doi: 10.1097/FJC.0000000000000687.
    PubMed     Abstract available


  97. TAKAHASHI M
    Cell-Specific Roles of NLRP3 Inflammasome in Myocardial Infarction.
    J Cardiovasc Pharmacol. 2019 Jul 22. doi: 10.1097/FJC.0000000000000709.
    PubMed     Abstract available


  98. BUCKLEY LF, Libby P
    Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes.
    J Cardiovasc Pharmacol. 2019 Jul 22. doi: 10.1097/FJC.0000000000000701.
    PubMed     Abstract available


  99. TRANKLE C, Wohlford G, Buckley LF, Kadariya D, et al
    Alirocumab in Acute Myocardial Infarction: Results from the Virginia Commonwealth University Alirocumab Response Trial (VCU-AlirocRT).
    J Cardiovasc Pharmacol. 2019 Jul 22. doi: 10.1097/FJC.0000000000000706.
    PubMed     Abstract available


  100. MARTON Z, Pataricza J, Pollesello P, Varro A, et al
    The novel inodilator ORM-3819 relaxes isolated porcine coronary arteries: role of voltage-gated potassium channels activation.
    J Cardiovasc Pharmacol. 2019 Jul 22. doi: 10.1097/FJC.0000000000000700.
    PubMed     Abstract available


  101. LI YH, Yang SS, Guo XH, Chen YD, et al
    Prophylactic use of mucosal protective agents and proton pump inhibitors in patients undergoing percutaneous coronary intervention: real world evidences of 36870 patients.
    J Cardiovasc Pharmacol. 2019 Jul 22. doi: 10.1097/FJC.0000000000000684.
    PubMed     Abstract available


  102. YAMAGATA K
    Soy isoflavones inhibit endothelial cell dysfunction and prevent cardiovascular disease.
    J Cardiovasc Pharmacol. 2019 Jul 22. doi: 10.1097/FJC.0000000000000708.
    PubMed     Abstract available


  103. YANG JB, Kang YM, Zhang C, Yu XJ, et al
    Infusion of melatonin into the paraventricular nucleus ameliorates myocardial ischemia-reperfusion injury by regulating oxidative stress and inflammatory cytokines.
    J Cardiovasc Pharmacol. 2019 Jul 22. doi: 10.1097/FJC.0000000000000711.
    PubMed     Abstract available


  104. MAURO AG, Bonaventura A, Mezzaroma E, Quader M, et al
    The NLRP3 inflammasome in acute myocardial infarction.
    J Cardiovasc Pharmacol. 2019 Jul 12. doi: 10.1097/FJC.0000000000000717.
    PubMed     Abstract available


  105. JOOST VAN ESDONK M, Stevens J, Stuurman FE, de Boon WMI, et al
    The pharmacodynamic effects of a dopamine-somatostatin chimera agonist on the cardiovascular system.
    J Cardiovasc Pharmacol. 2019 Jul 11. doi: 10.1097/FJC.0000000000000695.
    PubMed     Abstract available


  106. YOSHIDA R, Ishii H, Morishima I, Tanaka A, et al
    Impact of Post-Discharge Bleeding on Long-Term Mortality in Percutaneous Coronary Intervention Patients Taking Oral Anticoagulants.
    J Cardiovasc Pharmacol. 2019 Jul 11. doi: 10.1097/FJC.0000000000000702.
    PubMed     Abstract available


  107. MISHRA A, Singh M, Acker WW, Kamboj S, et al
    Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
    J Cardiovasc Pharmacol. 2019 Jul 11. doi: 10.1097/FJC.0000000000000697.
    PubMed     Abstract available


  108. WU J, Ye Y, Li C, Zhou W, et al
    Correlation of Inhaled Long-acting Bronchodilators with Adverse Cardiovascular Outcomes in Patients with Stable COPD: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2019 Jul 11. doi: 10.1097/FJC.0000000000000705.
    PubMed     Abstract available


    May 2019
  109. PUCHULU MB, Arreche N, Zotta E, Donato M, et al
    Erythropoietin Improves Cardiovascular Function in Adult Rats After Acute Hemorrhage.
    J Cardiovasc Pharmacol. 2019;73:290-300.
    PubMed     Abstract available


  110. CHEN W, Chen XY, Wang Y, Wang HY, et al
    Mechanism of Emulsified Isoflurane Postconditioning-Induced Activation of the Nrf2-Antioxidant Response Element Signaling Pathway During Myocardial Ischemia-Reperfusion: The Relationship With Reactive Oxygen Species.
    J Cardiovasc Pharmacol. 2019;73:265-271.
    PubMed     Abstract available


    March 2019
  111. PUCHULU MB, Arreche N, Zotta E, Donato M, et al
    Erythropoietin improves cardiovascular function in adult rats after acute hemorrhage.
    J Cardiovasc Pharmacol. 2019 Mar 14. doi: 10.1097/FJC.0000000000000666.
    PubMed     Abstract available


  112. SALAH E, Bastacky SI, Jackson EK, Tofovic SP, et al
    2-Methoxyestradiol Attenuates Angiotensin II-Induced Hypertension, Cardiovascular Remodeling, and Renal Injury.
    J Cardiovasc Pharmacol. 2019;73:165-177.
    PubMed     Abstract available


    February 2019
  113. KAWADA T, Yamazaki T, Akiyama T, Hayama Y, et al
    Mild Hypothermia Is Ineffective to Protect Against Myocardial Injury Induced by Chemical Anoxia or Forced Calcium Overload.
    J Cardiovasc Pharmacol. 2019;73:100-104.
    PubMed     Abstract available


  114. SINGH H, Kumar M, Singh N, Jaggi AS, et al
    Late Phases of Cardioprotection During Remote Ischemic Preconditioning and Adenosine Preconditioning Involve Activation of Neurogenic Pathway.
    J Cardiovasc Pharmacol. 2019;73:63-69.
    PubMed     Abstract available


    December 2018
  115. MOMCILOVIC S, Milovanovic JR, Jankovic SM, Jovanovic A, et al
    Population pharmacokinetic analysis of bisoprolol in patients with acute coronary syndrome.
    J Cardiovasc Pharmacol. 2018 Dec 10. doi: 10.1097/FJC.0000000000000644.
    PubMed     Abstract available


    November 2018
  116. LEENEN FH, Ahmad M, Marc Y, Llorens-Cortes C, et al
    Specific Inhibition of Brain Angiotensin III formation as a new strategy for prevention of heart failure after myocardial infarction.
    J Cardiovasc Pharmacol. 2018 Nov 30. doi: 10.1097/FJC.0000000000000638.
    PubMed     Abstract available


  117. LIU XW, Lu MK, Zhong HT, Wang LH, et al
    Panax Notoginseng Saponins Attenuate Myocardial Ischemia Reperfusion Injury via the HIF-1alpha/BNIP3 Pathway of Autophagy.
    J Cardiovasc Pharmacol. 2018 Nov 30. doi: 10.1097/FJC.0000000000000640.
    PubMed     Abstract available


  118. TIAN X, Zhou Y, Wang Y, Zhang S, et al
    Mitochondrial Dysfunction and Apoptosis are Attenuated upon kappa-Opioid Receptor Activation via AMPK/GSK-3beta Pathway Following Myocardial Ischemia and Reperfusion.
    J Cardiovasc Pharmacol. 2018 Nov 5. doi: 10.1097/FJC.0000000000000635.
    PubMed     Abstract available


    October 2018
  119. BOOZ GW
    Seizing the Future: What's next for the Journal of Cardiovascular Pharmacology?
    J Cardiovasc Pharmacol. 2018 Oct 30. doi: 10.1097/FJC.0000000000000630.
    PubMed    


  120. PIQUERAS-FLORES J, Jurado-Roman A, Lopez-Lluva MT, Sanchez-Perez I, et al
    Efficacy and safety of loading doses with P2Y12-receptor antagonists in patients without dual antiplatelet therapy undergoing elective coronary intervention.
    J Cardiovasc Pharmacol. 2018 Oct 30. doi: 10.1097/FJC.0000000000000632.
    PubMed     Abstract available


  121. YUAN L, Tang C, Li D, Yang Z, et al
    microRNA-18a expression in female coronary heart disease and regulatory mechanism on endothelial cell by targeting estrogen receptorsss.
    J Cardiovasc Pharmacol. 2018 Oct 24. doi: 10.1097/FJC.0000000000000623.
    PubMed     Abstract available


    June 2018
  122. DIMITROULIS D, Golabkesh M, Naguib D, Knoop B, et al
    Safety and efficacy in Prasugrel vs. Ticagrelor treated ST-elevation myocardial infarction (STEMI) patients.
    J Cardiovasc Pharmacol. 2018 Jun 27. doi: 10.1097/FJC.0000000000000609.
    PubMed     Abstract available


  123. ZHOU L, Liu X, Wang ZQ, Li Y, et al
    Simvastatin Treatment Protects Myocardium in Non-coronary Artery Cardiac Surgery by Inhibiting Apoptosis Through miR-15a-5p Targeting.
    J Cardiovasc Pharmacol. 2018 Jun 27. doi: 10.1097/FJC.0000000000000611.
    PubMed     Abstract available


    May 2018
  124. VAN TAUNAY JS, Albelda MT, Frias JC, Lipinski MJ, et al
    Biologics and Cardiovascular Disease.
    J Cardiovasc Pharmacol. 2018 May 3. doi: 10.1097/FJC.0000000000000595.
    PubMed     Abstract available


    April 2018
  125. CHEN S, Zhang S, Luan H, Zeng X, et al
    Correlation Between Extended Leukocyte Differential Count and Coronary Artery Disease.
    J Cardiovasc Pharmacol. 2018 Apr 10. doi: 10.1097/FJC.0000000000000582.
    PubMed     Abstract available


  126. SALAH EM, Bastacky SI, Jackson EK, Tofovic SP, et al
    Captopril Attenuates Cardiovascular and Renal Disease in a Rat Model of Heart Failure With Preserved Ejection Fraction.
    J Cardiovasc Pharmacol. 2018;71:205-214.
    PubMed     Abstract available


    March 2018
  127. ABOUZAKI NA, Christopher S, Trankle C, Van Tassell BW, et al
    Inhibiting the inflammatory injury following myocardial ischemia reperfusion with plasma derived alpha-1 anti-trypsin: a post-hoc analysis of the VCU-alpha1RT study.
    J Cardiovasc Pharmacol. 2018 Mar 23. doi: 10.1097/FJC.0000000000000583.
    PubMed     Abstract available


  128. BISGAIER CL, Oniciu DC, Srivastava RAK
    Comparative Evaluation of Gemcabene and PPAR Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease.
    J Cardiovasc Pharmacol. 2018 Mar 21. doi: 10.1097/FJC.0000000000000580.
    PubMed     Abstract available


  129. MOHAMMAD FIC AM, Al-Allawi NA
    CYP2C19 genotype is an independent predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel Post Percutaneous Coronary Intervention.
    J Cardiovasc Pharmacol. 2018 Mar 12. doi: 10.1097/FJC.0000000000000577.
    PubMed     Abstract available


  130. DARWESH AM, El-Azab MF, Abo-Gresha NM, El-Sayed NM, et al
    Cardioprotective Mechanisms of Exenatide in Isoprenaline-induced Myocardial Infarction: Novel Effects on Myocardial alpha-Estrogen Receptor Expression and IGF-1/IGF-2 System.
    J Cardiovasc Pharmacol. 2018;71:160-173.
    PubMed     Abstract available


    February 2018
  131. DUAN Q, Xu Y, Marck PV, Kalisz J, et al
    Preconditioning and Postconditioning by Cardiac Glycosides in the Mouse Heart.
    J Cardiovasc Pharmacol. 2018;71:95-103.
    PubMed     Abstract available


    January 2018
  132. SIGURDSSON MI, Waldron NH, Bortsov AV, Smith SB, et al
    Genomics of Cardiovascular Measures of Autonomic Tone.
    J Cardiovasc Pharmacol. 2018 Jan 3. doi: 10.1097/FJC.0000000000000559.
    PubMed     Abstract available


    December 2017
  133. ABBATE A
    Why the CANTOS Is a Game Changer in Cardiovascular Medicine.
    J Cardiovasc Pharmacol. 2017;70:353-355.
    PubMed    


    September 2017
  134. JAZMIN FM, Diana RH, Citali SH, Diego LM, et al
    Sex Differences In Vascular Reactivity To Angiotensin Ii During The Evolution Of Myocardial Infarction.
    J Cardiovasc Pharmacol. 2017 Sep 29. doi: 10.1097/FJC.0000000000000542.
    PubMed     Abstract available


    June 2017
  135. ZHONG Y, Zhong P, He S, Zhang Y, et al
    Trimetazidine Protects Cardiomyocytes Against Hypoxia/Reoxygenation Injury by Promoting AMP-activated Protein Kinase-dependent Autophagic Flux.
    J Cardiovasc Pharmacol. 2017;69:389-397.
    PubMed     Abstract available


    May 2017
  136. HARISSEH R, Chiari P, Villedieu C, Sueur P, et al
    Cyclophilin D Modulates the Cardiac Mitochondrial Target of Isoflurane, Sevoflurane, and Desflurane.
    J Cardiovasc Pharmacol. 2017;69:326-334.
    PubMed     Abstract available


  137. VECSERNYES M, Szokol M, Bombicz M, Priksz D, et al
    Alpha-Melanocyte-stimulating Hormone Induces Vasodilation and Exerts Cardioprotection Through the Heme-Oxygenase Pathway in Rat Hearts.
    J Cardiovasc Pharmacol. 2017;69:286-297.
    PubMed     Abstract available


    April 2017
  138. BEHMENBURG F, Pickert E, Mathes A, Heinen A, et al
    The Cardioprotective Effect of Dexmedetomidine in Rats Is Dose-Dependent and Mediated by BKCa Channels.
    J Cardiovasc Pharmacol. 2017;69:228-235.
    PubMed     Abstract available


    March 2017
  139. ZHU A, Wei X, Zhang Y, You T, et al
    Propofol Provides Cardiac Protection by Suppressing the Proteasome Degradation of Caveolin-3 in Ischemic/Reperfused Rat Hearts.
    J Cardiovasc Pharmacol. 2017;69:170-177.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ischemic Heart Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: